Cover Image
市場調查報告書

全球大腸癌症診斷、治療藥市場 (各診斷、技術、地區) :預測 (2015年∼2020年)

Global Colorectal Cancer Diagnostics & Therapeutics Market - Segmented by diagnosis, technology and geography (2016-2021)

出版商 Mordor Intelligence LLP 商品編碼 353905
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
全球大腸癌症診斷、治療藥市場 (各診斷、技術、地區) :預測 (2015年∼2020年) Global Colorectal Cancer Diagnostics & Therapeutics Market - Segmented by diagnosis, technology and geography (2016-2021)
出版日期: 2016年03月01日 內容資訊: 英文
簡介

全球大腸癌症診斷、治療藥市場,預計2015年∼2020年以1∼5%的年複合成長率成長。

本報告提供全球大腸癌症診斷、治療藥市場相關調查分析,市場概要,推動市場要素、阻礙因素、機會,各市場區隔的市場分析,競爭情形,主要企業等,有系統的資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會

第4章 波特的五力分析

第5章 市場區隔

  • 各診斷
  • 各治療
  • 各地區

第6章 競爭情形

  • M&A
  • 契約、夥伴關係、聯盟
  • 新產品的銷售
  • 建議

第7章 企業簡介

  • Abbott Diagnostics
  • Alere
  • Beckman Coulter
  • Clinical Genomic
  • Companion Dx
  • EDP Biotech
  • Epigenomics AG
  • Exact Sciences
  • FUJIREBIO
  • Genomic Tree
  • Metabiomics
  • Oncocyte (Biotime)
  • Quest Diagnostics
  • Randox Laboratories
  • Siemens Healthcare
  • Volition Rx

第8章 附錄

目錄

The global colorectal cancer diagnostics and therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 1-5% during the forecast period of 2015-2020. The market is valued at USD 14,143 million, as per 2015.

The CRC pipeline is highly robust, with a number of potential drug candidates present across the various phases of clinical development. With nearly 400 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or as second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as promising immunotherapies and chemotherapy drug candidates. Along with these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.

The global colorectal cancer diagnostics and therapeutics market is segmented on the basis of:

Diagnosis

  • Digital rectal examination
  • Fecal occult blood test
  • Flexible sigmoidoscopy
  • Colonoscopy
  • Others

Treatments

  • Surgery and radiation therapy
  • Targeted therapies
  • Others

Geography

  • North America
  • Asia-Pacific
  • Europe
  • Rest of the world

Some of the key players of the market are Abbott diagnostics, Alere, Beckman coulter, clinical genomics, Companion DX, EDP Biotech, Epigenomics AG, Exact sciences, Genomic tree, Metabiomics, Oncocyte, Quest Diagnostics, Randox Laboratories, Siemens Healthcare etc.

Drivers:

  • Increase of pipeline colorectal cancer screening tests
  • Aging population
  • Increasing consumer awareness

Restraints:

  • Cost of screening test
  • Counselling

Table of Contents

1. Introduction

  • 1.1. Report Description
  • 1.2. Research Methodology

2. Executive summary

3. Market overview

  • 3.1. Market definition
  • 3.2. Market drivers
    • 3.2.1. Increase of Pipeline Colorectal Cancer Screening Tests
    • 3.2.2. Aging Population
    • 3.2.3. Increasing Consumer Awareness
  • 3.3. Market restraints
    • 3.3.1. screening test costs
    • 3.3.2. Counseling
  • 3.4. Market opportunities

4. Portors five force analysis

  • 4.1. Bargaining power of suppliers
  • 4.2. Bargaining power of buyers
  • 4.3. Degree of comprtition
  • 4.4. Threat of substitution
  • 4.5. Threat of new entrants

5. Market segmentation

  • 5.1. By diagnosis
    • 5.1.2. Digital Rectal Examination
    • 5.1.3. Fecal Occult Blood Test
    • 5.1.4. Flexible Sigmoidoscopy
    • 5.1.5. Colonoscopy
    • 5.1.6. Virtual Colonoscopy
  • 5.2. By treatment
    • 5.2.1. Surgery and Radiation Therapy
    • 5.2.2. Chemotherapy
    • 5.2.3. Targeted Therapies
    • 5.2.4. Resistance to Pharmacological Therapies
  • 5.3. By geography
    • 5.3.3. Middle East & Africa
      • 5.3.3.1. Qatar
      • 5.3.3.2. Saudi Arabia
      • 5.3.3.3. South Africa

6. Competitive Landscape

  • 6.1. Mergers & Acquisitions
  • 6.2. Agreements, Partnerships and Collaborations
  • 6.3. New Product Launches
  • 6.4. Recommendations to new market players

7. Company profiles

  • 7.1. Abbott Diagnostics
  • 7.2. Alere
  • 7.3. Beckman Coulter
  • 7.4. Clinical Genomics
  • 7.5. Companion Dx
  • 7.6. EDP Biotech
  • 7.7. Epigenomics AG
  • 7.8. Exact Sciences
  • 7.9. Fujirebio (Miraca Holdings)
  • 7.10. Genomic Tree
  • 7.11. Metabiomics
  • 7.12. Oncocyte (Biotime)
  • 7.13. Quest Diagnostics
  • 7.14. Randox Laboratories
  • 7.15. Siemens Healthcare
  • 7.16. Volition Rx

8. Appendix

  • 8.1. Abbreviations
  • 8.2. Sources
  • 8.3. Bibliography
  • 8.4. Disclaimer
Back to Top